Korsana Biosciences (KRSA) vs Nektar Therapeutics (NKTR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Korsana Biosciences (KRSA) has outperformed Nektar Therapeutics (NKTR) over the past year, gaining 90.0% versus a loss of 27.9%. Over five years, NKTR leads with a -84.3% price change compared with -91.1% for KRSA. Korsana Biosciences is the larger company by market cap ($1.54 billion vs $1.41 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRSA | NKTR |
|---|---|---|
| Share price | $33.92 | $41.17 |
| Market cap | $1.54B | $1.41B |
| 1-day change | +1.22% | +0.91% |
| YTD return | +276.94% | -3.50% |
| 1-year return | +89.97% | -27.86% |
| 5-year return | -91.10% | -84.29% |
| EPS (TTM) | $-7.07 | $-18.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.07M | — |
| Revenue growth (YoY) | +3.70% | — |
| Net income (latest FY) | $-3.53M | — |
| Operating margin | -239.78% | — |
| Net margin | -170.11% | — |
| 52-week high | $59.36 | $109.00 |
| 52-week low | $7.19 | $33.40 |
| Distance from 52-week high | -42.86% | -62.23% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +29.72% | +243.45% |
| Average volume | 32.06K | 1.07M |
| Shares outstanding | 45.54M | 34.14M |
| Employees | 19 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRSA has outperformed NKTR by 117.8 percentage points over the past year.
About Korsana Biosciences
KRSA stock →Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Nektar Therapeutics
NKTR stock →Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
KRSA vs NKTR FAQ
Which is bigger, Korsana Biosciences or Nektar Therapeutics?
Korsana Biosciences (KRSA) is larger, with a market capitalization of $1.54B compared with $1.41B for Nektar Therapeutics (NKTR).
Which stock has performed better over the past year, KRSA or NKTR?
KRSA returned +89.97% over the past 12 months, compared with -27.86% for NKTR (price return, excluding dividends). Past performance does not predict future results.
Are Korsana Biosciences and Nektar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.